Progress in systemic therapy for advanced-stage urothelial carcinoma

Nature Reviews Clinical Oncology, Published online: 09 November 2023; doi:10.1038/s41571-023-00826-2Patients with advanced-stage urothelial cancer (aUC) continue to have poor long-term survival outcomes. However, developments in the past 5 years, most notably the availability of maintenance therapy with the anti-PD-1 antibody avelumab, are beginning to change this issue. In this Review, the authors provide an overview of the treatment of patients with aUC, including considerations of the various promising new therapeutic modalities and how they might improve clinical outcomes.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research